AR062012A1 - Pirazoles como activadores de glucoquinasa - Google Patents
Pirazoles como activadores de glucoquinasaInfo
- Publication number
- AR062012A1 AR062012A1 ARP070103249A ARP070103249A AR062012A1 AR 062012 A1 AR062012 A1 AR 062012A1 AR P070103249 A ARP070103249 A AR P070103249A AR P070103249 A ARP070103249 A AR P070103249A AR 062012 A1 AR062012 A1 AR 062012A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- lower alkyl
- hydrogen
- alkyl
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Útiles para el tratamiento de enfermedades y trastornos metabólicos, con preferencia la diabetes mellitus. Reivindicación 1: Un compuesto de la fórmula (1) en la que R¹ y R² se eligen con independencia entre el grupo formado por hidrógeno, halógeno, amino, hidroxiamino, ciano, nitro, alquilo inferior, -OR⁵, -C(O)OR⁶, perfluoro-alquilo inferior, alquiltio inferior, perfluoro-alquiltio inferior, alquilsulfinilo inferior, alquilsulfonilo inferior, cicloalquil-alquilsulfonilo inferior, (alcoxi inferior)-alquilsulfonilo inferior, perfluoro-alquilsulfonilo inferior y sulfonamido; o R¹ y R², junto con el anillo fenilo, al que están unidos, se combinan para formar un grupo elegido entre el grupo formado por 2,3-dihidro-benzo[b]tiofeno, 1-óxido de 2,3-dihidro-benzo[b]tiofeno, 1,1-dióxido de 2,3-dihidro-benzo[b]tiofeno, benzo[b]tiofeno, 1-óxido de benzo[b]tiofeno, 1,1-dióxido de benzo[b]tiofeno, tiocromano, 1-óxido de tiocromano y 1,1-dióxido de tiocromano; R³ es un cicloalquilo, un bicicloalquilo o un heterociclo mono- o bicíclico de 1-3 heteroátomos, elegido entre N, O y S, dicho cicloalquilo o heterociclo está sin sustituir o mono-, bi- o trisustituido con grupos elegidos entre el grupo formado por halógeno, alquilo inferior, alcoxi inferior, carbonilo y alquilsulfonilo inferior; R⁴ se elige entre el grupo formado por hidrógeno, los compuestos del grupo de fórmulas (2), alquilo C₁₋₁₀ y alquenilo C₂₋₁₀; R⁵ se elige entre el grupo formado por hidrógeno, alquilo C₁₋₆, fenilo, bencilo, fenilo sustituido y bencilo sustituido; R⁶ se elige entre el grupo formado por hidrógeno, alquilo C₁₋₆, bencilo y bencilo sustituido; R⁷ se elige entre el grupo formado por hidrógeno, hidroxi, alcoxi, perfluoro-alcoxi, amino, alquilamino, dialquilamino, hidroximetilo, C(O)OY', en el que Y' es H o alquilo inferior y -O-C(O)-CH₃; R⁸ es hidrógeno o alquilo inferior; R⁹ se elige entre el grupo formado por hidrógeno, cicloalquilo y alquilo inferior; R¹⁰ se elige entre el grupo formado por hidroxi, alcoxi inferior, amino, metilamino, dimetilamino o -NH-CH₂-cicloalquilo; R¹¹ se elige entre el grupo formado por hidroxi, amino, alquilamino inferior, ciclopropil-metil-amino, metoxi y NHCH₂CH₂CH₂L, en el que L es metoxi, hidroxi o dimetilamino; R¹² es hidrógeno o alquilo inferior; R¹³ es hidrógeno o alquilo inferior; R¹⁴ se elige entre el grupo formado por hidrógeno, alquilo inferior, SO₂X, en el que X es alquilo inferior, y C(O)Y, en el que Y es alquilo inferior u O-alquilo; R¹⁵ se elige entre el grupo formado por hidroxi, metoxi, t-butoxi, alquilo inferior, 2-hidroxi-2-metil-propilo, amino, metilamino, propilamino, dimetilamino, dietilamino, morfolino, fenilamino, bencilamino, alilcarbamoil-alquilo inferior, alilamino, pirazin-2-ilamino y NH-(CH₂)ᵛZ, en el que Z es metoxi o morfolino; R¹⁶ es alquilo inferior; R¹⁷ es metoxi; R¹⁸ se elige entre el grupo formado por hidrógeno, alquilo inferior y C(O)R', en el que R' es alquilo inferior; X e Y se eligen con independencia entre el grupo formado por hidrógeno, halógeno, ciano, alquilo inferior, metoxi, SO₂X, en el que X es alquilo y cicloalquilo; m es el número 0, 1, 2, 3 ó 4; en el que, si m es 0, R⁷ no puede ser hidroxi, alcoxi, perfluoro-alcoxi, amino, alquilamino ni dialquilamino; n es el número 0, 1 ó 2; p es el número 0 ó 1; q es el número 0, 1 ó 2; y v es el número 2 ó 3; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83290706P | 2006-07-24 | 2006-07-24 | |
US93081907P | 2007-05-18 | 2007-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR062012A1 true AR062012A1 (es) | 2008-08-10 |
Family
ID=38657003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070103249A AR062012A1 (es) | 2006-07-24 | 2007-07-20 | Pirazoles como activadores de glucoquinasa |
Country Status (16)
Country | Link |
---|---|
US (1) | US7935699B2 (es) |
EP (2) | EP2046755A2 (es) |
JP (1) | JP2009544648A (es) |
KR (1) | KR20090025358A (es) |
AR (1) | AR062012A1 (es) |
AU (1) | AU2007278261A1 (es) |
BR (1) | BRPI0715531A2 (es) |
CA (1) | CA2657566A1 (es) |
CL (1) | CL2007002121A1 (es) |
IL (1) | IL196321A0 (es) |
MX (1) | MX2009000688A (es) |
NO (1) | NO20090064L (es) |
PE (1) | PE20080406A1 (es) |
RU (1) | RU2009105818A (es) |
TW (1) | TWI332948B (es) |
WO (1) | WO2008012227A2 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200831081A (en) * | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
WO2008111473A1 (ja) * | 2007-03-07 | 2008-09-18 | Kyorin Pharmaceutical Co., Ltd. | グルコキナーゼ活性化物質 |
RU2010134411A (ru) * | 2008-01-18 | 2012-02-27 | Астеллас Фарма Инк. (Jp) | Фенилацетамидное производное |
US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
CA2722733C (en) | 2008-04-28 | 2016-02-23 | Kyorin Pharmaceutical Co., Ltd. | Cyclopentylacrylamide derivative |
UA104742C2 (uk) * | 2008-12-19 | 2014-03-11 | Эли Лилли Энд Компани | Похідні арилциклопропілацетаміду, застосовні як активатори глюкокінази |
US20110021570A1 (en) * | 2009-07-23 | 2011-01-27 | Nancy-Ellen Haynes | Pyridone glucokinase activators |
CN102762792B (zh) * | 2010-02-23 | 2014-06-25 | 世联株式会社 | 透湿防水布 |
CN102959076B (zh) | 2010-03-31 | 2015-09-16 | 斯克里普斯研究所 | 重编程细胞 |
US8178689B2 (en) | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
EP2402327B1 (en) | 2010-06-29 | 2018-03-07 | Impetis Biosciences Ltd. | Acetamide compounds as glucokinase activators, their process and medicinal applications |
AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
PL2655375T3 (pl) | 2010-12-23 | 2015-05-29 | Sanofi Sa | Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie |
US8470866B2 (en) | 2011-05-03 | 2013-06-25 | Hoffmann-La Roche Inc. | Isoindolinone derivatives |
CN104662013A (zh) * | 2012-09-26 | 2015-05-27 | 兴和株式会社 | 新型的苯基乙酰胺化合物及含有其的药物 |
TR201816624T4 (tr) | 2014-06-03 | 2018-11-21 | Idorsia Pharmaceuticals Ltd | Pirazol bileşikleri ve t tipi kalsiyum kanalı bloke edicileri olarak kullanımları. |
SG11201701998XA (en) | 2014-09-15 | 2017-04-27 | Actelion Pharmaceuticals Ltd | Triazole compounds as t-type calcium channel blockers |
BR112019011208A2 (pt) | 2016-12-16 | 2019-10-15 | Idorsia Pharmaceuticals Ltd | combinação farmacêutica, composição farmacêutica, e, kit de partes. |
CN110234622B (zh) | 2017-02-06 | 2023-07-04 | 爱杜西亚药品有限公司 | 用于合成1-芳基-1-三氟甲基环丙烷的新颖方法 |
CN108947940A (zh) * | 2018-06-20 | 2018-12-07 | 天津全和诚科技有限责任公司 | 一种2-氧杂环丁烷衍生物的合成方法 |
CN108727309B (zh) * | 2018-06-20 | 2023-04-07 | 天津全和诚科技有限责任公司 | 一种3-氧杂环丁烷羧酸的合成方法 |
CN109053496B (zh) * | 2018-08-09 | 2020-10-20 | 吉尔生化(上海)有限公司 | 一种3-Boc-氨甲基环丁酮的合成方法 |
CN114940658A (zh) * | 2022-05-12 | 2022-08-26 | 山东华阳药业有限公司 | 一种色瑞替尼的制备工艺及其制备方法 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100455635B1 (ko) | 1999-03-29 | 2004-11-06 | 에프. 호프만-라 로슈 아게 | 글루코키나제 활성화제 |
AU7049401A (en) | 2000-05-03 | 2001-11-12 | Hoffmann La Roche | Alkynyl phenyl heteroaromatic glucokinase activators |
BR0110703A (pt) | 2000-05-08 | 2003-01-28 | Hoffmann La Roche | Amida, composição farmacêutica que compreende um composto, compostos, utilização de compostos, processos para o tratamento profilático ou terapêutico de diabetes do tipo ii e para a preparação desses compostos |
DE60106599T2 (de) | 2000-05-08 | 2006-02-09 | F. Hoffmann-La Roche Ag | Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren |
AU2190202A (en) | 2000-12-06 | 2002-06-18 | Hoffmann La Roche | Fused heteroaromatic glucokinase activators |
SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
ES2276097T3 (es) | 2002-04-26 | 2007-06-16 | F. Hoffmann-La Roche Ag | Fenilacetamidas sustituidas y su empleo0 como activadores de glucoquinasa. |
NZ539013A (en) | 2002-10-03 | 2007-05-31 | Novartis Ag | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes |
US7132425B2 (en) | 2002-12-12 | 2006-11-07 | Hoffmann-La Roche Inc. | 5-substituted-six-membered heteroaromatic glucokinase activators |
EP1594863A1 (en) | 2003-02-11 | 2005-11-16 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
PL378117A1 (pl) * | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
US7629362B2 (en) | 2003-02-13 | 2009-12-08 | Banyu Pharmaceutical Co., Ltd. | 2-pyridine carboxamide derivatives |
MXPA05009059A (es) * | 2003-02-26 | 2005-10-19 | Banyu Pharma Co Ltd | Derivados de heteroarilcarbamoilbenceno. |
EP1718625A1 (en) | 2004-02-18 | 2006-11-08 | AstraZeneca AB | Compounds |
WO2005080359A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Benzamide derivatives and their use as glucokinae activating agents |
CA2560286A1 (en) | 2004-03-23 | 2005-09-29 | Banyu Pharmaceutical Co., Ltd. | Substituted quinazoline or pyridopyrimidine derivative |
CA2561157A1 (en) | 2004-04-02 | 2005-10-13 | Novartis Ag | Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions |
JP4700684B2 (ja) | 2004-04-02 | 2011-06-15 | ノバルティス アーゲー | 2型糖尿病の処置に有用なグルコキナーゼアクティベーターとしてのスルホンアミド−チアゾロピリジン誘導体 |
WO2005103021A1 (en) | 2004-04-21 | 2005-11-03 | Prosidion Limited | Tri(cyclo) substituted amide compounds |
TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
GB0418046D0 (en) * | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Eantioselective process |
BRPI0514147A (pt) * | 2004-08-12 | 2008-05-27 | Prosidion Ltd | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de tratamento profilático ou terapêutico de uma condição onde a ativação de gk é desejável, de tratamento profilático ou terapêutico da hiperglicemia ou diabete e de prevenção da diabete em um ser humano que demosntra hiperglicemia pré-diabética ou toleráncia à glicose prejudicada, e, processo para a preparação do composto |
GB0423044D0 (en) | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
EP1824835A1 (en) | 2004-12-03 | 2007-08-29 | Novo Nordisk A/S | Heteroaromatic glucokinase activators |
TW200714597A (en) | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
WO2007007040A1 (en) | 2005-07-09 | 2007-01-18 | Astrazeneca Ab | 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes |
US20080234273A1 (en) | 2005-07-09 | 2008-09-25 | Mckerrecher Darren | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes |
NZ575514A (en) | 2005-07-09 | 2009-11-27 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
CA2613303C (en) | 2005-07-11 | 2012-06-19 | Mitsubishi Tanabe Pharma Corporation | An oxime derivative for use as a glucokinase activator |
JP2009504621A (ja) | 2005-08-09 | 2009-02-05 | アストラゼネカ アクチボラグ | 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体 |
US20090281142A1 (en) | 2005-08-31 | 2009-11-12 | Astellas Pharma Inc. | Thiazole derivative |
GT200600428A (es) * | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
BRPI0618067A2 (pt) * | 2005-11-03 | 2011-08-16 | Prosidion Ltd | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso e processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo |
CA2626475A1 (en) * | 2005-11-03 | 2007-05-10 | Prosidion Limited | Tricyclo substituted amides |
US20080293741A1 (en) | 2005-11-03 | 2008-11-27 | Matthew Colin Thor Fyfe | Tricyclo Substituted Amides as Glucokinase Modulators |
JP5302012B2 (ja) | 2006-03-08 | 2013-10-02 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤 |
EP2463283B1 (en) | 2006-04-20 | 2014-06-11 | Pfizer Products Inc. | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases |
-
2007
- 2007-07-16 EP EP07787582A patent/EP2046755A2/en not_active Withdrawn
- 2007-07-16 CA CA002657566A patent/CA2657566A1/en not_active Abandoned
- 2007-07-16 BR BRPI0715531-0A2A patent/BRPI0715531A2/pt not_active IP Right Cessation
- 2007-07-16 WO PCT/EP2007/057315 patent/WO2008012227A2/en active Application Filing
- 2007-07-16 KR KR1020097001515A patent/KR20090025358A/ko not_active Application Discontinuation
- 2007-07-16 AU AU2007278261A patent/AU2007278261A1/en not_active Abandoned
- 2007-07-16 EP EP10175986A patent/EP2261216A3/en not_active Withdrawn
- 2007-07-16 MX MX2009000688A patent/MX2009000688A/es not_active Application Discontinuation
- 2007-07-16 JP JP2009521210A patent/JP2009544648A/ja active Pending
- 2007-07-16 RU RU2009105818/04A patent/RU2009105818A/ru not_active Application Discontinuation
- 2007-07-19 US US11/879,935 patent/US7935699B2/en not_active Expired - Fee Related
- 2007-07-20 CL CL200702121A patent/CL2007002121A1/es unknown
- 2007-07-20 AR ARP070103249A patent/AR062012A1/es not_active Application Discontinuation
- 2007-07-20 TW TW096126648A patent/TWI332948B/zh not_active IP Right Cessation
- 2007-07-23 PE PE2007000954A patent/PE20080406A1/es not_active Application Discontinuation
-
2009
- 2009-01-01 IL IL196321A patent/IL196321A0/en unknown
- 2009-01-06 NO NO20090064A patent/NO20090064L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2007278261A1 (en) | 2008-01-31 |
TWI332948B (en) | 2010-11-11 |
MX2009000688A (es) | 2009-01-30 |
TW200812974A (en) | 2008-03-16 |
CA2657566A1 (en) | 2008-01-31 |
PE20080406A1 (es) | 2008-04-28 |
WO2008012227A2 (en) | 2008-01-31 |
EP2261216A2 (en) | 2010-12-15 |
US20080021032A1 (en) | 2008-01-24 |
US7935699B2 (en) | 2011-05-03 |
WO2008012227A3 (en) | 2008-05-15 |
EP2261216A3 (en) | 2011-12-14 |
JP2009544648A (ja) | 2009-12-17 |
RU2009105818A (ru) | 2010-08-27 |
BRPI0715531A2 (pt) | 2014-06-24 |
CL2007002121A1 (es) | 2008-02-22 |
WO2008012227A8 (en) | 2008-09-12 |
NO20090064L (no) | 2009-02-04 |
KR20090025358A (ko) | 2009-03-10 |
IL196321A0 (en) | 2009-09-22 |
EP2046755A2 (en) | 2009-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR062012A1 (es) | Pirazoles como activadores de glucoquinasa | |
AR063081A1 (es) | Derivados de 3- aza- biciclo [3.1.0] hexano y su uso para la preparacion de medicamentos | |
AR122776A2 (es) | Composiciones parasiticidas que comprenden un agente activo de isoxazolina, sus métodos y usos | |
AR064561A1 (es) | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. | |
AR108256A2 (es) | Un método para el control de nematodos parásitos de plantas | |
AR062510A1 (es) | Derivados de piridona con actividad antagonista de mch y medicamentos que comprenden estos compuestos | |
AR070459A1 (es) | Derivados de 2-aza-biciclo- [2,2,1] heptano | |
AR058362A1 (es) | Derivados de isoquinolina - aminopirazol su obtencion y su utilizacion como agentes farmaceuticos | |
AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
AR012825A1 (es) | Piridinas substituidas como inhibidores selectivos de ciclooxigenasa 2, una composicion farmaceutica que las contiene y su uso para la fabricacion de medicamentos | |
AR071323A1 (es) | Derivados heterociclicos de piridazinonas activadores de glucoquinasas, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de la diabetes mellitus tipo ii. | |
ES2213007T3 (es) | Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2. | |
AR054280A1 (es) | Derivados de carboxamidas y su empleo en procedimientos de lucha contra enfermedades de plantas y contra hongos nocivos | |
AR079224A1 (es) | Compuestos insecticidas basados en derivados de isoxazolina | |
AR056204A1 (es) | Derivados de indano como antagonistas de receptores de mch, metodos para su preparacion, intermediarios de sintesis de los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades relacionadas | |
PE20191817A1 (es) | Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4) | |
AR103265A1 (es) | Compuestos de azolina sustituidos con un sistema de anillos condensado | |
AR074909A1 (es) | Compuestos de imina para combatir plagas de invertebrados | |
AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
AR105544A1 (es) | Compuestos de n-carboxamida cíclica útiles como herbicidas | |
AR068547A1 (es) | Derivados de quinolina | |
AR065822A1 (es) | Derivados de tiazolidina. composiciones farmaceuticas y usos como antagonistas del receptor orexina | |
AR107249A1 (es) | Compuestos depsipeptídicos como anthelmínticos | |
AR067662A1 (es) | Derivados de benzo[d]isoxazol-3-il-piperidina, medicamentos que los contienen y usos terapeuticos para enfermedades asociadas al sistema nervioso. | |
AR083635A1 (es) | Compuestos y derivados sustituidos de isoxazolina que contienen azolin para combatir plagas animales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |